Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 524-538

  Walsh, Sharon L ^a,d   Sullivan, John T ^a,b   Preston, Kenzie L ^a,c   Garner, Jane E ^a   Bigelow, George E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYER CORPORATION   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; HYDROMORPHONE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MIXTURE; HEROIN DEPENDENCE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE DRUG ABUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS TRANSMISSION;

ADULT; BUPRENORPHINE; COCAINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; HYDROMORPHONE; LIVER; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; RESPIRATION; SUBSTANCE-RELATED DISORDERS;

EID: 0030433661     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. AVANTS, S. K., MARGOLIN, A. AND KOSTEN, T. R.: Cocaine abuse in methadone maintenance programs: Integrating pharmacotherapy with psychosocial interventions. J. Psychoactive Drugs 26: 137-146, 1994.
2. BAIN, G. T. AND KORNETSKY, C.: Naloxone attenuation of the effect of cocaine on rewarding brain stimulation. Life Sci. 40: 1119-1125, 1986.
3. BATTJEE, R. J., PICKENS, R. W., HAVERKOS, H. W. AND SLOBODA, Z.: HIV risk factors among injecting drug users in five cities. AIDS 8: 681-687, 1994.
4. BROWN, E. E., FINLAY, J. M., WONG, J. T. F., DAMSMA, G. AND FIBIGER, H. C.: Behavioral and neurochemical interactions between cocaine and buprenorphine: Implications for the pharmacotherapy of cocaine abuse. J. Pharmacol. Exp. Ther. 256: 119-126, 1991.
5. BYCK, R., RUSKIS, A., UNGERER, J. AND JATLOW, P.: Naloxone potentiates cocaine effect in man. Psychopharmacol. Bull. 18: 214-215, 1982.
6. CARROLL, M. E., LAC, S. T., WALKER, M. J., KRAGH, R. AND NEWMAN, T.: Effects of naltrexone on intravenous cocaine self-administration in rats during food satiation and deprivation. J. Pharmacol. Exp. Ther. 238: 1-7, 1986.
7. CONDELLI, W. S., FAIRFANK, J. A., DENNIS, M. L. AND RACHEL, J. V.: Cocaine use by clients in methadone programs: Significance, scope, and behavioral interventions. J. Subst. Abuse Treat. 8: 203-212, 1991.
8. CORRIGALL, W. A. AND COEN, K. M.: Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology 104: 167-170, 1991.
9. CROWLEY, T. J., WAGNER, J. E., ZERBE, G. AND MACDONALD, M.: Naltrexone-induced dysphoria in former opioid addicts. Am. J. Psychiatry 142: 1081-1084, 1985.
10. DE VRY, J., DONSELAAR, I. AND VAN REE, J. M.: Food deprivation and acquisition of intravenous cocaine self-administration in rats: Effect of naltrexone and haloperidol. J. Pharmacol. Exp. Ther. 251: 735-740, 1989.
11. DI CHIARA, G. AND IMPERATO, A.: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 85: 5274-5278, 1988.
12. DOLAN, M. P., BLACK, J. L., DEFORD, H. A., SKINNER, J. R. AND ROBINOWITZ, R.: Characteristics discriminating needle-sharing among drug abusers. Public Health Rep. 102: 395-398, 1986.
13. DOLAN, M. P., BLACK, J. L., PENK, W. E., ROBINOWITZ, R. AND DEFORD, H. A.: Predicting the outcome of contingency contracting for drug abuse. Behav. Ther. 17: 470-474, 1987.
14. DYKSTRA, L. A., DOTY, P., JOHNSON, A. B. AND PICKER, M. J.: Discriminative stimulus properties of cocaine, alone and in combination with buprenorphine, morphine and naltrexone. Drug Alcohol Depend. 30: 227-234, 1992.
15. ETTENBERG, A., PETTIT, H. O., BLOOM, F. E. AND KOOB, G. F.: Heroin and cocaine intravenous self-administration in rats: Mediation by separate neural systems. Psychopharmacology 78: 204-209, 1982.
16. FINGERHOOD, M. I., JASINSKI D. R. AND SULLIVAN J. T.: Prevalence of Hepatitis C in a chemically dependent population. Arch. Intern. Med. 153: 2025-2030, 1993.
17. FISCHMAN, M. W., SCHUSTER, C. R., RESNEKOV, L., SHICK, J. E., KRASNEGOR, N. A., FENNELL, W. AND FREEDMAN, D. X.: Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch. Gen. Psychiatry 33: 983-989, 1976.
18. FOLTIN, R. W., CHRISTIANSEN, I., LEVIN, F. R. AND FISCHMAN, M. W.: Effects of single and multiple intravenous cocaine injections in humans maintained on methadone. J. Pharmacol. Exp. Ther. 275: 38-47, 1995.
19. FOLTIN, R. W. AND FISCHMAN, M. W.: Smoked and intravenous cocaine in humans: Acute tolerance, cardiovascular and subjective effects. J. Pharmacol. Exp. Ther. 257: 247-261, 1991.
20. FOLTIN, R. W. AND FISCHMAN, M. W.: The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. J. Pharmacol. Exp. Ther. 261: 623-632, 1992.
21. FOLTIN, R. W. AND FISCHMAN, M. W.: Effects of buprenorphine on the self-adminstration of cocaine by humans. Behav. Pharmacol. 5: 79-89, 1994.
22. GATCH, M. B., NEGUS, S. S., BUTELMAN, E. R. AND MELLO, N. K.: (1995) Antinociceptive effects of cocaine/opioid combinations in rhesus monkeys. J. Pharmacol. Exp. Ther. 275: 1346-1354.
23. HAERTZEN, C. A.: An Overview of the Addiction Research Center Inventory (ARCI): An Appendix and Manual of Scales. DHEW Pub. No. 79, Department of Health Education and Welfare, Washington, D.C., 1974.
24. HEMBY, S. E., SMITH, J. AND DWORKIN, S.: The effects of eticlopride and naltrexone on responding maintained by food, cocaine, and cocaine/heroin combinations in rats. J. Pharmacol. Exp. Ther. 277: 1247-1258, 1996.
25. HOLLISTER, L. E., JOHNSON, K., BOUKHABZA, D. AND GILLESPIE, H. K.: Aversive effects of natlrexone in subjects not dependent on opiates. Drug Alcohol Depend. 8: 37-41, 1981.
26. HOUDI, A. A., BARDO, M. T. AND VAN LOON, G. R.: Opioid mediation of cocaine-induced hyperactivity and reinforcement. Brain Res. 497: 195-199, 1989.
27. JAFFE, J. H. AND MARTIN, W. R.: Opioid analgesics and antagonists. In The Pharmacological Basis of Therapeutics, 7th ed., ed. by A. G. Goodman, L. S. Goodman, T. W. Rall, and F. Murad, pp. 491-531, Macmillan Publishing Company, New York, 1985.
28. JARBE, T-C.: Cocaine cue in pigeons: Time course studies and generalization to structurally related compounds (norcocaine, WIN 35, 428, and 35, 065-2) and (+) amphetamine. Br. J. Pharmacol. 73: 843-852, 1981.
29. JASINSKI D. R.: Progress report from the Clinical Pharmacology Section of the NIDA Addiction Research Center. In Proceedings of the 39th Annual Scientific Meeting, The Committee on Problems of Drug Dependence, pp. 133-168, National Research Council, National Academy of Sciences, Washington, D.C., 1977.
30. KAMIEN, J. B. AND SPEALMAN, R. D.: Modulation of the discriminative stimulus effects of cocaine by buprenorphine. Behav. Pharmacol. 2: 517-520, 1991.
31. KILLIAN, A. K., BONESE, K. AND SCHUSTER, C. R.: The effects of naloxone on behavior maintained by cocaine and heroin injections in the rhesus monkeys. Drug Alcohol Depend. 3: 243-251, 1978.
32. KLOSS, M. W., ROSEN, G. M. AND RAUCKMAN, E. J.: Cocaine-mediated hepatotoxicity - A critical review. Biochem. Pharmacol. 33: 169-173, 1984.
33. KOOB, G. F. AND BLOOM, F. E.: Cellular and molecular mechanisms of drug dependence. Science 242: 715-723, 1988.
34. KOSTEN, T. R., KLEBER, H. D. AND MORGAN, C.: Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 44: 887-892, 1989.
35. KOSTEN, T. R., ROUNSAVILLE, B. J., GAWIN, F. H. AND KLEBER, H. D.: Cocaine abuse among opioid addicts: Demographic and diagnostic factors in treatment. Am. J. Drug Alcohol Abuse 12: 1-16, 1986.
36. KOSTEN, T., SILVERMAN, D. G., FLEMING, J., KOSTEN, T. A., GAWIN, F. H., COMPTON, M., JATLOW, P. AND BYCK, R.: Intravenous cocaine challenges during naltrexone maintenance: A preliminary study. Biol. Psychiatry 32: 543-548, 1992.
37. KUHAR, M. J., PERT, C. B. AND SNYDER, S. H.: Regional distribution of opiate receptor binding in monkey and human brain. Nature 245: 447-450, 1973.
38. KUHAR, M. J., RITZ, M. C. AND BOJA, J. W.: The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurol. Sci. 14: 299-302, 1991.
39. LAMB, R. J. AND HENNINGFIELD, J. E.: Human d-amphetamine drug discrimination: Methamphetamine and hydromorphone. J. Exp. Anal. Behav. 61: 169-180, 1994.
40. MAHLER, D. L. AND FORREST, JR., W. H.: Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology 42: 602-607, 1975.
41. MALOW, R. M., WEST, J. A., CORRIGAN, S. A., PENA, J. M. AND LOTT, W. C.: Cocaine and speedball users: Differences in psychopathology. J. Sub. Abuse Treat. 9: 287-291, 1992.
42. MARTIN, W. R., JASINSKI, D. R. AND MANSKY, P. A.: Naltrexone, an antagonist for the treatment of heroin dependence - Effects in man. Arch. Gen. Psychiatry 28: 784-791, 1973.
43. MASUKAWA, Y., SUZUKI, T. AND MISAWA, M.: Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines. Psychopharmacology 111: 139-143, 1993.
44. MCCAUL, M. E., STITZER, M. L., BIGELOW, G. E. AND LIEBSON, I. A.: Intravenous hydromorphone: Effects in opiate-free and methadone maintenance subjects. In Problems of Drug Dependence, The Committee on Problems of Drug Dependence, NIDA Research Monograph 43, ed. by L. S. Harris, pp. 238-244, U.S. Department of Health and Human Services, Rockville, 1982.
45. MEANDZIJA, B., O'CONNOR, P. G., FITZGERALD, B., ROUNSAVILLE, B. J. AND KOSTEN, T. R.: HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend. 36: 109-113, 1994.
46. MELLO, N. K., MENDELSON, J. H., BREE, M. P. AND LUKAS, S. E.: Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 254: 926-939, 1990.
47. MELLO, N. K, NEGUS, S. S., LUKAS, S. E., MENDELSON, J. H., SHOLAR, J. W. AND DRIEZE, J.: A primate model of polydrug abuse: Cocaine and heroin combinations. J. Pharmacol. Exp. Ther. 274: 1325-1337, 1995.
48. MENDELSON, J. H., ELLINGBOE, J., KEUHNLE, J. C. AND MELLO, N. K.: Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 3: 231-236, 1979.
49. MENKENS, K., BILSKY, E. J., WILD, K. D., PORTOGHESE, P. S., REID, L. D. AND PORRECA, F.: Cocaine place preference is blocked by the 5-opioid receptor antagonist, naltrindole. Eur. J. Pharmacol. 219: 345-346, 1992.
50. MISRA, A. L., PONTANI, R. B. AND BADLAMANI, N. L.: Stereospecific potentiation of opiate analgesia by cocaine: Predominant role of noradrenaline. Pain 28: 129-138, 1987.
51. MONTI, K. M., FOLTZ, R. L. AND CHINN, D. M.: Analysis of naltrexone and 6-β-naltrexol in plasma and urine by gas chromatography/negative ion chemical ionization mass spectrometry. J. Anal. Toxicol. 15: 136-140, 1991.
52. NATIONAL HOUSEHOLD SURVEY ON DRUG ABUSE: POPULATION ESTIMATES 1992, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, SUBSTANCE ABUSE MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA), U.S. GOVERNMENT PRINTING OFFICE, DHHS 93-2053, WASHINGTON, D.C., 1993.
53. NATIONAL HOUSEHOLD SURVEY ON DRUG ABUSE: POPULATION ESTIMATES 1993, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, SUBSTANCE ABUSE MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA), U.S. GOVERNMENT PRINTING OFFICE, DHHS 94-3017, WASHINGTON, D.C., 1994.
54. NEGUS, S. S., MELLO N. K., PORTOGHESE, P. S., LUKAS, S. E. AND MENDELSON, J. H.: Role of delta opioid receptors in the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 273: 1245-1256, 1995.
55. NEMOTO, T.: Patterns of cocaine use and HIV infection among injection drug users in a methadone clinic. J. Substance Abuse 6: 169-178, 1994.
56. NOTT, M. W.: Potentiation of morphine analgesia in mice. Eur. J. Pharmacol. 5: 93-99, 1968.
57. PERTOVAARA, A., MECKE, E. AND CARLSON, S.: Attempted reversal of cocaine-induced antinociceptive effects with naloxone, an opioid antagonist. Eur. J. Pharmacol. 192: 349-353, 1991.
58. PHYSICIANS DESK REFERENCE, 49TH ED. Medical Economics Data Production Company, Montvale, NJ, 1995.
59. PINI, L. A., FERRETTI, C., TRENTI, T., FERRARI, A. AND STERNIERI, E.: Effects of long-term treatment with naltrexone on hepatic enzyme activity. Drug Met. Drug Interact. 9: 161-174, 1991.
60. PRESTON, K. L. AND BIGELOW, G. E.: Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J. Pharmacol. Exp. Ther. 264: 813-823, 1993.
61. PRESTON, K. L., BIGELOW, G. E. AND LIEBSON, I. A.: Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology 94: 484-490, 1988.
62. PRESTON, K. L., SULLIVAN, J. T., BERGER, P. AND BIGELOW, G. E.: Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J. Pharmacol. Exp. Ther. 267: 296-307, 1993.
63. PRESTON, K. L., SULLIVAN J. T., STRAIN E. C. AND BIGELOW, G. E.: Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J. Pharmacol. Exp. Ther. 262: 279-291, 1992.
64. PRESTON, K. L., SULLIVAN J. T., STRAIN E. C. AND BIGELOW, G. E.: Enhancement of cocaine's abuse liability in methadone maintenance patients. Psychopharmacology 123: 15-25, 1996.
65. RAMSEY, N. F. AND VAN REE, J. M.: Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 40: 807-810, 1991.
66. RESNICK, R. B., KESTENBAUM, R. S. AND SCHWARTZ, L. K.: Acute systemic effects of cocaine in man: A controlled study by intranasal and intravenous routes. Science 195: 696-699, 1977.
67. RITZ, M. C., CONE, E. J. AND KUHAR, M. J.: Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: A structure-activity study. Life Sci. 46: 635-645, 1990.
68. RITZ, M. C., LAMB, R. J., GOLDBERG, S. R. AND KUHAR, M. J.: Cocaine receptors on dopamine transporters are related to self-administration. Science 237: 1219-1223, 1987.
69. SAX, D. S., KORNETSKY, C. AND KIM, A.: Lack of hepatotoxicity with naltrexone treatment. J. Clin. Pharmacol. 34: 898-901, 1994.
70. SCHAEFFER, G. J.: Opiate antagonist and rewarding brain stimulation. Neurosci. Biobehav. Rev. 12: 1-17, 1988.
71. SIEGAL, H. A., CARLSON, R. G., WANG, J., FALCK, R. S., STEPHENS, R. C. AND NELSON, E. D.: Injection drug users in the midwest: An epidemiologic comparison of drug use patterns in four Ohio cities. J. Psychoactive Drugs 26: 265-275, 1994.
72. SIERRA, V., DUTTAROY, A., LUFTY, K., CANDIDO, J., BILLINGS, B., ZITO, S. W. AND YOBURN, B. C.: Potentiation of opioid analgesia by cocaine: The role of spinal and supraspinal receptors. Life Sci. 50: 591-597, 1992.
73. SPEALMAN, R. D. AND BERGMAN, J.: Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. J. Pharmacol. Exp. Ther. 261: 607-615, 1992.
74. SPEALMAN, R. D. AND BERGMAN, J.: Opioid modulation of the discriminative stimulus effects of cocaine: Comparison of μ, κ, δ agonists in squirrel monkeys discriminating low doses of cocaine. Behav. Pharmacol. 5: 21-31, 1994.
75. SPITZER, R. L. AND WILLIAMS, J. B. W.: Structured Clinical Interview for DSM-III-R Patient Version SCID-P, (5-1-86), New York State Psychiatric Institute, American Psychiatric Press, Washington, D.C., 1986.
76. STRAIN, E. C., PRESTON, K. L., STITZER M. L., LIEBSON, I. A. AND BIGELOW, G. E.: The effects of cocaine in buprenorphine-maintained outpatient volunteers. Am. J. Addict. 3: 129-143, 1994.
77. STRAIN, E. C., STITZER, M. L., LIEBSON, I. A. AND BIGELOW, G. E.: Methadone dose and treatment outcome. Drug Alcohol Depend. 33: 105-117, 1993.
78. TEOH, S. K., MELLO, N. K., MENDELSON, J. H., KUEHNLE, J., GASTFRIEND, D. R., RHOADES, E. AND SHOLAR, W.: Buprenorphine effects on morphine- and cocaine-induced subjective response by drug-dependent men. J. Clin. Psychopharmacol. 14: 15-27, 1994.
79. TEOH, S. K., MENDELSON, J. H., MELLO, N. K., KUEHNLE, J., PRADIT, S. AND RHOADES, E. M.: Acute interactions of buprenorphine with intravenous cocaine and morphine: An investigational new drug phase I safety evaluation. J. Clin. Psychopharmacol. 13: 87-99, 1993.
80. VEREBEY, K., VOLAVKA, J., MULE, S. J. AND RESNICK, R. B.: Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharm. Ther. 20: 315-328, 1976.
81. VEREBEY, K.: The clinical pharmacology of naltrexone: Pharmacology and pharmacodynamics. In Naltrexone: Research Monograph, 28, ed. by R. E. Willette and G. Barnett, National Institute on Drug Abuse, pp. 147-158, U.S. Government Printing Office, Washington, D.C., 1980.
82. WALSH, S. L., PEESTON, K. L., SULLIVAN, J. T., FROMME, R. F. AND BIGELOW, G. E.: Fluoxetine alters the effects of intravenous cocaine in humans. J. Clin. Psychopharmacol. 14: 396-407, 1994.
83. WIECHMAN, B. E., WOOD, T. E. AND SPRATTO, G. R.: Locomotor activity in morphine-treated rats: Effects of and comparisons between cocaine, procaine and lidocaine. Pharmacol. Biochem. Behav. 15: 425-433, 1981.
84. WINGER, G., SKJOLDAGER, P. AND WOODS, J. H.: Effects of buprenorphine and other opioid agonists and antagonists on alfentanil- and cocaine-reinforced responding in rhesus monkeys. J. Pharmacol. Exp. Ther. 261: 311-317, 1992.
85. WISE, R. A. AND BOZARTH, M. A.: A psychomotor stimulant theory of addiction. Psychol. Rev. 94: 469-492, 1987.
86. WOOD, P. L.: Opioid regulation of CNS dopaminergic pathways: A review of methodology, receptor types, regional variations and species differences. Peptides 4: 595-601, 1983.
87. WOOD, D. M. AND EMMETT-OGLESBY, M. W.: Characteristics of tolerance, recovery from tolerance, and cross-tolerance for cocaine used as a discriminative stimulus. J. Pharmacol. Exp. Ther. 237: 120-125, 1986.